Oligodendrocytes, the cells that build and repair myelin in the brain and spinal cord, may play a role in the inflammatory processes involved in multiple sclerosis (MS), even at the earliest stages of disease, according to a study in a mouse model. “We found that oligodendrocytes transition to disease…
News
More than 3 million doses of Vueway (gadopiclenol), a lower-dose gadolinium contrast MRI agent used to diagnose and monitor conditions such as multiple sclerosis (MS), have been administered at more than 900 customer sites, maker Bracco Diagnostics said. Approved by the U.S. Food and Drug Administration for use in children…
Simultaneously measuring levels of two blood proteins — glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) — may offer a clearer way to track both disease activity and disability progression in people with multiple sclerosis (MS), according to a new long-term study. Each…
A Phase 2 clinical trial testing PIPE-307, an experimental therapy designed to support myelin repair in people with multiple sclerosis (MS), has failed to meet its primary or secondary efficacy goals. The U.S.-based VISTA trial (NCT06083753) enrolled more than 180 adults with relapsing-remitting MS (RRMS). Participants received…
Tyruko (natalizumab-sztn) is now commercially available in the U.S. as the first and only approved biosimilar to Tysabri for adults with relapsing forms of multiple sclerosis (MS). The therapy received approval from the U.S. Food and Drug Administration (FDA) in 2023 for all indications covered by the…
A clinical trial is now recruiting participants to test whether an experimental vaccine for the Epstein-Barr virus (EBV) is safe and may help reduce disease activity in people with multiple sclerosis (MS). The Phase 2 study (NCT06735248) aims to enroll 180 adults, ages 18 to 55, with…
Multiple sclerosis (MS) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) share similar symptoms but are two biologically distinct conditions, with different immune signatures, a study found. These findings help explain why treatments approved for MS generally show limited effectiveness for MOGAD, researchers said. “These findings support MOGAD as its…
Zydus Lifesciences received final approval from the U.S. Food and Drug Administration (FDA) to market a generic version of Vumerity (diroximel fumarate) for adults with relapsing forms of multiple sclerosis (MS) and other conditions. The drug will be sold as 231 mg delayed-release capsules, produced at Zydus’s…
Mesenchymal stem cell therapy shows promise for treating multiple sclerosis (MS), with improvements seen in disability, walking ability, vision, and auditory function, according to a recent review of published studies. The approach also seems to be well tolerated by people with MS, but more research is needed on…
A new technique is letting scientists peer into the brain’s wiring with greater detail by simply using a microscope and an LED light, an accessible and cost-effective method that may be useful for studying brain damage in neurological diseases such as multiple sclerosis (MS). The method, called Computational Scattered…
Genentech‘s experimental oral therapy fenebrutinib has become the first Bruton’s tyrosine kinase (BTK) inhibitor to show positive Phase 3 results in both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS), the company announced. In what Genentech called “unprecedented results,” two late-stage trials testing…
A new wearable brain-mapping tool could dramatically change how doctors monitor people with multiple sclerosis (MS), making it easier to track disease progression and guide personalized care. Researchers showed the system, OPM-MEG, reliably detects abnormalities in the brain’s electrical activity in MS patients. The portable technology is a major…
When the lights come up at the MS Focus on Fashion gala, the runway will be more than a showcase for beautiful designs. The Nov. 14 event in Fort Lauderdale, Florida, will be a celebration of confidence and connection for people living with multiple sclerosis (MS), according to…
Scientists at Case Western Reserve University (CWRU) in Ohio will use a new $2.5 million donation from the Thomas F. Peterson Jr. Charitable Trust to develop therapeutic strategies for multiple sclerosis (MS) and other neurological diseases. The commitment will support Paul Tesar, PhD, a CWRU professor and director of the…
Sativex (nabiximols) — a cannabis-based oral spray used to ease spasticity in certain people with multiple sclerosis (MS) — has been acquired by CNX Therapeutics, which will now market the therapy in Europe and other international regions. The therapy, previously developed by Jazz Pharmaceuticals, is approved as…
Researchers have developed a highly sensitive imaging technique that can detect damage to myelin, the fatty wrapping around nerve fibers that is damaged in multiple sclerosis (MS), in large areas of the brain, according to a study. The tool may help assess the extent of myelin damage in…
A robotic exoskeleton dubbed Atalante X, which allows people with severe mobility issues to stand upright for rehabilitation exercises, is now cleared by the U.S. Food and Drug Administration (FDA) for use by people with multiple sclerosis (MS) and a broader range of individuals with spinal cord injuries. Additionally,…
SUDO-550, an oral TYK2 inhibitor being developed by Sudo Biosciences, was found to be safe, well-tolerated, and to fully reach the brain in a first-in-human clinical trial involving healthy volunteers, according to clinical trial results. The Phase 1 clinical trial, which began dosing late last year, also showed…
Ultraviolet light therapy may help reduce inflammation and disease severity in people with multiple sclerosis (MS), according to data from a small Phase 1 clinical trial. Researchers used Octave’s MS Disease Activity (MSDA) scale — a clinically validated test for monitoring MS disease activity — and found the majority…
People with multiple sclerosis (MS) tend to have high levels of antibodies targeting the Epstein-Barr virus (EBV), but levels of these antibodies are not associated with disease activity or clinical worsening among MS patients. That’s according to the study, “Evaluating the role of anti-EBV antibodies…
People living with multiple sclerosis (MS) have consistently lower quality of life than the general population — regardless of age or gender, a new study shows. The scientists also identified several factors that are significantly associated with worse quality of life in MS. These included disease symptoms such as…
A third of adults live with chronic physical conditions such as multiple sclerosis (MS), but in most cases these conditions aren’t obvious to others — and many people downplay their impact to avoid making those around them uncomfortable. That’s according to a new report from Convatec, a medical…
Enrollment is complete for the randomized part of ENHANCE, a large clinical trial testing a new dosing schedule for Briumvi (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (MS), developer TG Therapeutics announced. This part of the Phase 3b ENHANCE study (NCT05877963) is specifically testing whether…
Eating more carbohydrates is significantly associated with a higher risk of developing multiple sclerosis (MS), particularly among women and people younger than 60, according to a study based on data from the U.K. “Higher intakes of total carbohydrates, total sugars, fiber, fructose, and glucose were significantly associated with increased…
Metis Biotech‘s experimental oral therapy MTS-004 was safe and eased symptoms of pseudobulbar affect (PBA), a neurological condition marked by bouts of sudden, involuntary, and inappropriate laughter or crying, in people with multiple sclerosis (MS) and other neurological disorders. That’s according to data from a Phase 3 clinical…
Obexelimab, a therapy Zenas Biopharma is developing for a range of autoimmune diseases, almost completely prevented the formation of new inflammatory lesions in adults with relapsing forms of multiple sclerosis (MS) in the first three months of a clinical trial. That’s according to data from the first part…
Bionxt Solutions has launched the final animal study needed to prepare for human testing of BNT23001, its sublingual version of cladribine, in people with multiple sclerosis (MS). The 15-day dosing optimization study will compare Bionxt’s thin-film formulation with the approved tablet version of cladribine, sold as Mavenclad, in…
People with multiple sclerosis (MS) have altered levels of bacteria in their mouths, with reduced levels of normal healthy bacteria and higher levels of bacteria that can cause disease, a new study reports. “Your mouth may reveal more about your overall health than you think,” Ashutosh Mangalam, PhD, senior…
The first patient has been dosed in a Phase 1 clinical trial of Autolus Therapeutics‘ experimental CAR T-cell therapy, obecabtagene autoleucel (obe-cel), in people with progressive forms of multiple sclerosis (MS) who have failed to respond to existing treatments. Dosing took place at University College London Hospitals NHS…
Researchers have identified a protein that naturally slows myelin production — a finding that could lead to ways to repair myelin damage in multiple sclerosis (MS) and other neurological disorders. In mice, the protein (called Tfii-i) was found to limit the activity of genes that drive myelin formation. When…